Expert Interview
A Second Look: Discussing the PASO DOBLE (GeSIDA 11720 study), the largest head-to-head, phase IV randomised clinical trial (RCT) investigating the 2-drug regimen Dovato compared to the 3-drug regimen Biktarvy for the treatment of HIV-1
Ticker(s): GSK, GILDInstitution: Montgomery Infectious Disease Associates
- Infectious Disease Physician at Montgomery Infectious Disease Associates
- Areas of expertise include HIV, Lyme disease and Nosocomial infections
- Familiar with VAX-31 phase 1/2 data
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
